December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CASI Pharmaceuticals, Inc. - Ordinary Shares (NQ:CASI)

0.8487 +0.0247 (+3.00%)
Streaming Delayed Price Updated: 1:24 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CASI Pharmaceuticals, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
These stocks have an unusual volume in today's session 
Via Chartmill
News headline image
CASI Pharmaceuticals Provides Business and Clinical Update
Via ACCESS Newswire
News headline image
Recap: CASI Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
Via ACCESS Newswire
News headline image
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish ↗
The company said that its special committee of the board of directors will evaluate the proposed transaction. 
Via Stocktwits
News headline image
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
Via ACCESS Newswire
News headline image
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
Via ACCESS Newswire
News headline image
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
News headline image
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Via ACCESSWIRE
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 ↗
CASI stock results show that CASI Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks You Can Pick Up for Less Than $10 ↗
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. 
Via InvestorPlace
News headline image
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary ↗
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 ↗
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients ↗
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.